Alston & Bird represent plaintiff Sandoz Inc. in an antitrust lawsuit against Amgen. Munger, Tolles & Olson and Kaufman & Canoles represent Amgen in a related case in the Eastern District of Virginia.

A federal appeals court upheld two patents protecting Amgen’s blockbuster drug, Enbrel, against biosimilar competition, Biopharma Dive reported. Amgen has been in a yearslong legal battle with the ...

Alston & Bird allege their client has suffered more than $1 billion in lost sales from being unable to manufacture a biosimilar product in the United States to compete with Amgen's blockbuster Enbrel ...

Negotiations to set prices Medicare will pay for the original branded version of etanercept, Enbrel, should bring the government some genuine savings, and may indirectly make it more affordable for ...

On Jan. 1, 2026, the price of my medication finally came down — and it will change my life. I have been living with psoriatic arthritis for over 40 years, a condition that I treat with a medication ...

(RTTNews) - Sandoz (SDZNY) has initiated an antitrust lawsuit in the United States against Amgen, Inc. (AMGN), accusing the company of maintaining its dominant market position for the blockbuster drug ...

Generic drugmaker Sandoz (OTCQX:SDZXF) announced on Monday the filing of an antitrust lawsuit alleging that Amgen (NASDAQ:AMGN) used certain patent-related tactics to extend its U.S. market dominance ...

Sandoz Group AG (OTC:SDZNY) (OTC:SDZXF) on Monday filed an antitrust lawsuit in the U.S. against Amgen, Inc. (NASDAQ:AMGN) for extending and entrenching the dominant market position of its blockbuster ...

Bottles of medicine ride on a belt at a mail-in pharmacy warehouse in Florence, N.J., July 10, 2018. President Joe Biden’s administration announced Tuesday, the first prescription drugs being targeted ...